Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia.
Fodstad
Philip
P
Dheyauldeen
Sinan
S
Rinde
Marit
M
Bachmann-Harildstad
Gregor
G
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D004844:Epistaxis / Q000209:etiology; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000503:physiopathology; D016896:Treatment Outcome; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006397:Hematinics; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab
Laryngoscope. 2004 Apr;114(4):705-9
15064628
N Engl J Med. 2009 May 14;360(20):2143-4
19439755
Laryngoscope. 2009 Feb;119(2):284-8
19160429
Am J Rhinol. 2006 Jan-Feb;20(1):87-90
16539301
Liver Transpl. 2008 Feb;14(2):210-3
18236396
Ann Hematol. 2006 Sep;85(9):631-2
16807748